MedComm – Biomaterials and Applications,
Journal Year:
2024,
Volume and Issue:
3(4)
Published: Dec. 1, 2024
Abstract
With
the
development
of
nanosystems,
they
are
gradually
utilized
to
ameliorate
diverse
cancer
therapies.
Specifically
for
immunotherapy,
most
nanosystems
elaborately
designed
initiate
self‐sustaining
“cancer
immunity
cycle
(CIC)”
elicit
immune
response.
However,
owing
highly
complex
circulatory
environment,
may
face
issues
like
nonspecific
nanoparticle
uptake
and
rapid
clearance,
leaving
enormous
room
advancement.
For
employing
biomimetic
design
in
based
on
cell
membranes
(BNCMs)
inherit
various
functional
molecules
from
source
cells,
permitting
precise
tumor
targeting,
enhancing
blood
circulation,
conferring
more
desired
functionality
a
robust
To
take
full
advantage
BNCMs,
understanding
their
functions
immunotherapy
is
essential.
In
this
review,
unique
properties
BNCMs
derived
cells
main
preparation
strategies
introduced.
Subsequently,
recent
advances
improving
discussed
aspects
roles
particular
stages
CIC,
working
mechanisms
outer
highlighted.
Finally,
along
with
analysis
existing
bottlenecks
clinical
translation,
some
suggestions
future
put
forward.
Non-coding RNA Research,
Journal Year:
2024,
Volume and Issue:
9(3), P. 811 - 830
Published: March 30, 2024
Cancer
is
a
broad
name
for
group
of
diseases
in
which
abnormal
cells
grow
out
control
and
are
characterized
by
their
complexity
recurrence.
Although
there
has
been
progress
cancer
therapy
with
the
entry
precision
medicine
immunotherapy,
incidence
rates
have
increased
globally.
Non-coding
RNAs
form
circular
(circRNAs)
play
crucial
roles
pathogenesis,
clinical
diagnosis,
different
diseases,
including
cancer.
According
to
recent
studies,
circRNAs
appear
serve
as
accurate
indicators
therapeutic
targets
treatment.
However,
promising
candidates
cutting-edge
because
distinctive
structure,
stability,
wide
range
capabilities;
many
challenges
persist
that
decrease
applications
circRNA-based
therapeutics.
Here,
we
explore
replacement
therapy,
highlight
main
facing
therapies,
discuss
key
strategies
overcome
these
improve
advanced
innovative
therapies
based
on
long-term
health
effects.
Theranostics,
Journal Year:
2024,
Volume and Issue:
15(3), P. 965 - 992
Published: Dec. 2, 2024
Hepatocellular
carcinoma
(HCC)
remains
a
leading
cause
of
cancer-related
mortality
worldwide,
particularly
due
to
the
limited
effectiveness
current
therapeutic
options
for
advanced-stage
disease.
The
efficacy
traditional
treatments
is
often
compromised
by
intricate
liver
microenvironment
and
inherent
heterogeneity.
RNA-based
therapeutics
offer
promising
alternative,
utilizing
innovative
approach
targeting
aberrant
molecular
pathways
modulating
tumor
microenvironment.
integration
nanotechnology
in
this
field,
through
development
advanced
nanocarrier
delivery
systems,
especially
lipid
nanoparticles
(LNPs),
polymer
(PNPs),
bioinspired
vectors,
enhances
precision
RNA
therapies.
This
review
highlights
significant
progress
nanotherapeutics
HCC
treatment,
covering
micro
(miRNA),
small
interfering
(siRNA),
message
(mRNA),
activating
(saRNA)
mediated
gene
silencing,
protein
restoration,
activation,
cancer
vaccines,
concurrent
therapy.
It
further
comprehensively
discusses
prevailing
challenges
within
landscape
provides
forward-looking
perspective
on
potential
transform
treatment.
Journal of Nanotheranostics,
Journal Year:
2025,
Volume and Issue:
6(2), P. 10 - 10
Published: April 9, 2025
Nanotheranostics—where
nanoscale
materials
serve
both
diagnostic
and
therapeutic
functions—are
rapidly
transforming
gene
therapy
by
tackling
critical
delivery
challenges.
This
review
explores
the
design
engineering
of
various
nanoparticle
systems
(lipid-based,
polymeric,
inorganic,
hybrid)
to
enhance
stability,
targeting,
endosomal
escape
genetic
payloads.
We
discuss
how
real-time
imaging
capabilities
integrated
into
these
platforms
enable
precise
localization
controlled
release
genes,
improving
treatment
efficacy
while
reducing
off-target
effects.
Key
strategies
overcome
barriers
(such
as
proton
sponge
effect
photothermal
disruption)
achieve
nuclear
are
highlighted,
along
with
recent
advances
in
stimuli-responsive
that
facilitate
spatiotemporal
control
expression.
Clinical
trials
preclinical
studies
demonstrate
expanding
role
nanotheranostics
managing
cancer,
inherited
disorders,
cardiovascular
neurological
diseases.
further
address
regulatory
manufacturing
hurdles
must
be
for
widespread
clinical
adoption
nanoparticle-based
therapies.
By
synthesizing
progress
ongoing
challenges,
this
underscores
transformative
potential
effective,
targeted,
image-guided
delivery.
